TGA warns against high dose simvastatin 1 December, 2011 Michael Woodhead comments New dose limits and contraindications for simvasatin have been introduced by the TGA to reduce the risk of myopathy and rhabdomyolysis. In an advisory in the latest Medicines Safety Update, the regulatory agency says the previous maximum recommended dose of 80mg a day should only be used in exceptional circumstances. This site is intended for Registered Medical Practitioners. To make the most of Endocrinology Update, you need to be logged in. to get Endocrinology Update delivered to your inbox Browse our newsletter archive Advertisement Latest comments Most read Endocrinology Update on Twitter